About Us
Mission and Vision
Staff and Board of Directors
Our Partners
What is ALD?
Newborn Screening / Asymptomatic
Adrenal Insufficiency
Cerebral ALD
Adrenomyeloneuropathy (AMN)
Symptomatic Women
Clinical Trials & Research
Clinical Trials
Emerging Investigators
The Grey Zone
Resources
Externally-Led Patient-Focused Drug Development (EL-PFDD)
Financial Assistance
Frequently Asked Questions
Mental Health
Peer Mentor Program
Webinars
Other Resources
Get Involved
ALD Landscape Project
Annual Meeting and Patient Learning Academy
Community Calendar
Community Calls
ALD Family Weekend
Industry Advisory Council
Patient-Led Planning Committee
News
Contact Us
Donate
Back to News & Events
ALD Family Weekend 2022
Jun 23, 2022
Blog
Events
Posted By:
ALD Connect
Posted In:
Blog
Events
Share Article:
Previous
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
Next
Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)
